Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 12 May 2022, 06:00 HKT/SGT
Share:
    

Source: Novotech Health Holdings Pte Ltd
Novotech Sponsors Pre-ASCO China Summit: Go/No Go Decisions Based on Early Phase Oncology Trials

SYDNEY, May 12, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its CRO services to the US, is pleased to sponsor the Pre-ASCO China Summit 2022 event titled: Go/No Go Decisions Based on Early Phase Oncology Trials ('The Summit').

The Summit will feature insights from leading Novotech experts tapping decades of oncology clinical experience in the APAC region. They include:
- Dr. Ramandeep Sharma, Senior Medical Monitor, Novotech
- Dr. Vivian Gu, Head of Clinical Development & Regulatory, CMO, Novotech China

Register here: https://www.eventbrite.com/e/pre-asco-china-2-gono-go-decisions-based-on-early-phase-oncology-trials-tickets-330427145487

Event Date:
- China Time: 9:00-10:30 AM, Saturday, May 14, 2022
- US EST Time: 9:00-10:30 PM, Friday, May 13, 2022
- US PST Time: 6:00-7:30 PM, Friday, May 13, 2022
Language: English, with Chinese simultaneous translation
Venue: Live Zoom Webinar
Moderator:
- Dr. Li Yan, CMO, Brii Biosciences; Managing Director, United States Chinese Anti-Cancer Association (USCACA)

The Summit will start with a presentation by Novotech's Senior Medical Monitor Dr. Ramandeep Sharma titled: Approaches, Experiences, and considerations for early phase go/no go.

A panel discussion will follow featuring leading clinical specialists including:
- Dr. Jin Li, Shanghai East Hospital
- Dr. Li Yan, CMO, Brii Biosciences; Managing Director, USCACA
- Dr. Ramandeep Sharma, Senior Medical Monitor, Novotech
- Dr. Vivian Gu, Head of Clinical Development & Regulatory, CMO, Novotech China
- Dr. Xiaoxia Yan, Highthink
- Dr. Jianmin Fang, Co-founder, CEO & CSO, RemeGen
- Dr. Joseph Eid, Chief Medical Officer, Hengrui
- Dr. Jon Wigginton, Senior Advisor and Chairman SAB, Cullinan Oncology; Former Head of Immuno-Oncology Early Clinical Development, BMS

Earlier this month, Novotech announced the acquisition of US CRO, NCGS as part of a US service expansion program for its global base of clients.

Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies.

NCGS was established in 1984 in South Carolina with a biopharma client base. NCGS has a workforce of about 300 professionals across the US.

Novotech CEO Dr. John Moller said:

"This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs."

"Clients will receive seamless service, with a unified approach to systems and SOPs well developed," Moller said.

Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.

With more than 2,000 highly experienced professionals, clients benefit from strong site and Key Opinion Leader relationships, deep regulatory expertise, and the ability to accelerate clinical trials across the Asia Pacific and in particular China.

Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data.

Novotech has also partnered with virtual research organisation ObvioHealth to expedite trials leveraging remote technologies. This patient-centric approach improves subject retention and allows sponsors to reach populations outside major cities for clinical trial participation.

About Novotech Health Holdings

Novotech Health Holdings Pte. Ltd. ("Novotech") is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, Novotech and PPC. Novotech is a CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. It has been instrumental in the success of approximately 3,700 clinical trials across all trial phases and broad range of therapeutic areas. Novotech is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. For more information visit https://novotech-cro.com/contact

Media Contact
David James
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427


Topic: Press release summary
Source: Novotech Health Holdings Pte Ltd

Sectors: BioTech, Healthcare & Pharm, Clinical Trials
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Novotech Health Holdings Pte Ltd
May 5, 2022 09:00 HKT/SGT
Novotech Acquires US CRO NCGS, Expands Global Expertise
Feb 9, 2022 15:00 HKT/SGT
Novotech Recognized as Top 10 CRO in CenterWatch Global Site Relationship Benchmarking Report
Aug 26, 2020 10:00 HKT/SGT
Novotech the Asia-Pacific CRO Leader - Awarded '2020 Frost & Sullivan Asia-Pacific CRO Company of the Year'
July 13, 2020 19:00 HKT/SGT
Novotech Webinar: Why the Asia-Pacific is Attracting 10,000 Oncology Trials and How Biotechs Can Tap the Region
June 18, 2020 11:00 HKT/SGT
Novotech Partners with South Korea's Pusan National University Hospital
May 26, 2020 19:00 HKT/SGT
Novotech and Endpoints to present APAC Clinical Trial webinar series
Apr 29, 2020 21:00 HKT/SGT
Novotech Selected as CRO for Karyopharm's COVID-19 Clinical Study
Apr 28, 2020 19:00 HKT/SGT
Novotech COVID-19 Clinical Trial Clients Benefit from New Asia-Pacific Fast-Track Review Processes
Apr 8, 2020 18:00 HKT/SGT
Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity
Mar 20, 2020 20:30 HKT/SGT
Novotech CRO Tapped for Two Informa Citeline Awards for Excellence in Asia-Pacific Clinical Trials
More news >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: